Vitamin B1/Thiamine / ROS Cancer Research Results

VitB1/Thiamine, Vitamin B1/Thiamine: Click to Expand ⟱
Features:
VitB1/Thiamine
Vitamin B1 (thiamine) is an essential water-soluble vitamin required for carbohydrate metabolism and mitochondrial energy production. Its active form, thiamine pyrophosphate (TPP), is a cofactor for key enzymes including pyruvate dehydrogenase (PDH), α-ketoglutarate dehydrogenase (α-KGDH), and transketolase. In Alzheimer’s disease (AD), thiamine deficiency and reduced activity of thiamine-dependent enzymes have been repeatedly observed in brain tissue. Impaired glucose metabolism is a hallmark of AD (“type 3 diabetes” hypothesis), and thiamine-dependent enzyme dysfunction contributes to mitochondrial impairment, oxidative stress, and neuronal vulnerability. Experimental studies suggest thiamine and lipophilic derivatives (e.g., benfotiamine) may improve glucose metabolism, reduce advanced glycation end products (AGEs), attenuate oxidative stress, and modulate neuroinflammation. Clinical data are mixed but suggest possible benefit in selected populations or with higher-bioavailability derivatives.
Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that’s used to support nerve health, glucose metabolism, and potentially brain function, including in conditions like Alzheimer’s disease (AD) and diabetic neuropathy.
-fat-soluble form, so may absorb better when taken with a meal containing fat.
Condition / Purpose	       Typical Dose Range	Notes
Alzheimer’s Disease (AD)	300–600 mg/day	        Used in clinical trials (e.g., 300 mg twice daily)
Diabetic Neuropathy	        300–600 mg/day	        Most common clinical application
General Cognitive Support	150–300 mg/day	        Lower end for maintenance
High-dose experimental use	900–1,200 mg/day	Occasionally used under supervision in research

Alzheimer’s Disease Table: Vitamin B1 (Thiamine)

Rank Pathway / Axis AD / Neurodegeneration Context Normal Brain Context TSF Primary Effect Notes / Interpretation
1 Pyruvate dehydrogenase (PDH) activity PDH activity ↓ in AD; thiamine restores PDH flux Glucose oxidation support R, G Mitochondrial energy restoration PDH links glycolysis to TCA cycle; impairment contributes to cerebral hypometabolism in AD.
2 α-Ketoglutarate dehydrogenase (α-KGDH) α-KGDH ↓ in AD brain tissue TCA cycle support R, G Mitochondrial stabilization Enzyme reduction correlates with oxidative stress and neuronal vulnerability.
3 Transketolase / Pentose Phosphate Pathway (PPP) NADPH production ↑; oxidative stress ↓ Redox buffering R, G Antioxidant support Transketolase requires thiamine; PPP supports glutathione regeneration.
4 Mitochondrial bioenergetics ATP production ↑; mitochondrial efficiency ↑ Energy metabolism normalization R Bioenergetic restoration Addresses cerebral glucose hypometabolism seen in AD imaging studies.
5 Oxidative stress reduction ROS ↓; lipid peroxidation ↓ (reported) Redox balance support R, G Antioxidant effect (indirect) Improved mitochondrial function reduces ROS generation.
6 Advanced glycation end products (AGEs) AGE formation ↓ (reported with benfotiamine) Glycation moderation G Metabolic toxicity reduction Benfotiamine may reduce glycation-linked neuronal damage.
7 Neuroinflammation Inflammatory markers ↓ (model-dependent) Inflammation moderation R, G Secondary anti-inflammatory effect Likely indirect via improved metabolic and redox function.
8 Amyloid / tau pathology Indirect modulation reported in models G Disease-modifying potential (uncertain) No strong direct anti-amyloid mechanism; effects appear metabolic.
9 Clinical cognition outcomes Mixed results; some benefit with benfotiamine Safe at standard doses G Adjunctive support High-dose or derivative forms may show more promise than standard thiamine.
10 Bioavailability / derivative consideration Benfotiamine & lipid-soluble forms ↑ CNS penetration Well tolerated Translation constraint Standard thiamine has limited brain penetration; benfotiamine shows improved pharmacokinetics.

TSF: P = minimal immediate effect; R = metabolic enzyme activation; G = long-term neuroprotective adaptation.



Thiamine vs Benfotiamine Comparison Table

Feature Thiamine (Vitamin B1) Benfotiamine
Chemical form Water-soluble vitamin (thiamine hydrochloride or mononitrate) Lipid-soluble S-acyl thiamine derivative
Absorption mechanism Active transport (THTR-1/2) in small intestine Passive diffusion (lipophilic); higher bioavailability
Plasma thiamine levels Moderate increase with supplementation Significantly higher plasma thiamine after oral dosing
Brain penetration Limited; regulated transport Indirectly increases brain thiamine via systemic elevation; better tissue distribution
Activation Converted to thiamine pyrophosphate (TPP) intracellularly Converted to thiamine → TPP intracellularly
PDH / α-KGDH support Restores enzyme activity in deficiency Stronger elevation of transketolase & TPP-dependent activity (reported)
Pentose phosphate pathway (PPP) Supports transketolase → NADPH production More pronounced activation of transketolase reported
AGE reduction Limited direct evidence Strong evidence for reducing advanced glycation end products (AGEs)
Oxidative stress impact Indirect ROS reduction via improved metabolism Stronger reduction of glycation-related oxidative stress
AD clinical evidence Mixed, limited benefit in trials Small trials suggest potential cognitive stabilization
Dose ranges studied (AD/metabolic) 100–300 mg/day (varies) 150–600 mg/day commonly studied
Safety profile Very safe; excess excreted in urine Generally safe; mild GI symptoms possible
Primary AD positioning Correct deficiency; metabolic support Enhanced metabolic + anti-glycation support
Best-fit scenario Thiamine deficiency; mild metabolic impairment Glucose dysregulation; high AGE burden; metabolic AD phenotype


ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


Scientific Papers found: Click to Expand⟱
4311- VitB1/Thiamine,    Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy
- in-vivo, AD, NA
*Aβ↓, *p‑tau↓, *ROS↓, *cognitive↑, *OS↑, *Mood↑, *neuroP↑, *Inflam↓, *NRF2↑, *PGC-1α↑, *AGEs↓, *4-HNE↓, *NQO1↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *GSK‐3β↓,
4314- VitB1/Thiamine,    Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology
- Review, AD, NA
*Risk↓, *GlucoseCon↑, *cognitive↑, *ATP↑, *ROS↓, *NADPH↑, *Aβ↓, *APP↓, *BACE↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

4-HNE↓, 1,   NQO1↑, 1,   NRF2↑, 1,   ROS↓, 2,  

Mitochondria & Bioenergetics

ATP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis

GlucoseCon↑, 1,   NADPH↑, 1,  

Proliferation, Differentiation & Cell State

GSK‐3β↓, 1,  

Migration

APP↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   IL1β↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission

p‑tau↓, 1,  

Protein Aggregation

AGEs↓, 1,   Aβ↓, 2,   BACE↓, 1,  

Functional Outcomes

cognitive↑, 2,   Mood↑, 1,   neuroP↑, 1,   OS↑, 1,   Risk↓, 1,  
Total Targets: 24

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:264  Target#:275  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page